Purchase this article with an account.
Maher Saleh, Sophie Lefevre, Francois Jehl, Gilles Prevost, David Gaucher, Arnaud Sauer, Claude Speeg, Tristan Bourcier; Intravitreal Injections Of Linezolid To Treat Experimental S. Aureus Endophthalmitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2933.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effects of intravitreal linezolid in an experimental rabbit model of Staphylococcus aureus endophthalmitis.
The right eyes of 22 rabbits weighing 2.5 to 3 kg were used. Ten thousand colony-forming units (CFU) of S. aureus in 0.1 ml saline solution were inoculated into the vitreous cavity. The eyes were randomly assigned to one of the five groups of 4, equally. Twenty-four hours after the inoculation of S. aureus, group 1 received 0.2 mg, group 2 received 1mg, group 3 received 10mg and group 4 received 30 mg of linezolid, while groupe 5 received 1 mg of vancomycin. The two remaining animals received Sham injections. Clinical examination scores were recorded everyday. Vitreous aspirates were obtained 1, 5, and 8 days after the inoculation for microbiological analysis. The eyes were enucleated for histopathologic examination at day 8. Statistical analysis was performed using Kruskal-Wallis and Mann-Whitney U tests.
Group 4 was the only one to display equal efficacy with the vancomycin group. Number of CFU and histopathologic score in this group were significantly lower compared with other linezolid groups (p < 0.05).
Intravitreal injection of linezolid in treating S. aureus endophthalmitis was only effective at high dose (30 mg). Caution should be taken in proposing linezolid for Gram + endophthalmitis.
This PDF is available to Subscribers Only